New data on fingolimod in RRMS


REPORT FROM THE 26TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH  IN MS (ECTRIMS), GOTHENBURG, SWEDEN, OCTOBER 13-16, 2010 – The oral agent fingolimod consistently reduces relapse rates regardless of disease severity or treatment history, and drug discontinuation is not associated with significant clinical complications, according to new studies and analyses presented at ECTRIMS.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page